<DOC>
	<DOCNO>NCT02140944</DOCNO>
	<brief_summary>IMPAACT P1107 describe outcomes HIV-infected person , age 12 month old , undergo transplantation CCR5Δ32 cord blood stem cell treatment cancer , hematopoietic disease , underlie disease .</brief_summary>
	<brief_title>IMPAACT P1107 : Effects Cord Blood Transplantation With CCR5Δ32 Donor Cells HIV Persistence</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Confirmed HIV1 infection 12 month age old Willing provide write informed consent PreTransplant Cohort : Underlying disease appropriate stem cell transplant , determine transplant team part standard care . PreTransplant Cohort : Availability appropriately match ( determined transplant center ) CCR5Δ32 cord blood unit ( homozygous heterozygous ) intention proceed transplantation . NOTE : Double cord transplant allow . If double cord use , least one cord blood unit CCR5∆32 ( homozygous heterozygous ) . PreTransplant Cohort : Received CCR5Δ32 homozygous cord blood bone marrow transplant within last two year . • Received , plan receive , one CCR5Δ32 homozygous cord blood bone marrow transplant .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cord blood transplantation</keyword>
	<keyword>CCR5Δ32</keyword>
	<keyword>HIV cure</keyword>
</DOC>